<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00450177</url>
  </required_header>
  <id_info>
    <org_study_id>052007738</org_study_id>
    <nct_id>NCT00450177</nct_id>
  </id_info>
  <brief_title>Efficacy of Enteral Iron Supplementation in Critical Illness</brief_title>
  <official_title>A Prospective, Randomized, Double-Blind, Placebo-Controlled Trial of the Effects of Enteral Iron Supplementation on Anemia and Risk of Infection in Critical Illness</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Weill Medical College of Cornell University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Weill Medical College of Cornell University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the efficacy of enteral iron supplementation for
      improving anemia, decreasing the risk of blood transfusion, and decreasing mortality in
      patients who are hospitalized in the intensive care unit. This study will also address any
      relationship between enteral iron supplementation and risk of infection.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Critical illness is characterized by the anemia of inflammation, which is partially caused by
      sequestration of iron from bone marrow sites of erythropoiesis into storage within the
      reticuloendothelial system as ferritin. Also the majority of critically ill patients are
      hypoferremia, the efficacy of iron supplementation remains unknown. Furthermore, several
      retrospective studies have found an association between iron overload and infection. However,
      the relative risk/benefit profile of enteral iron supplementation with respect to infection
      has not been studied. The purpose of this study is to evaluate the efficacy of enteral iron
      supplementation in critically ill patients. The hypothesis is that enteral iron
      supplementation will result in both an improved hematocrit and a decreased need for blood
      transfusion, without increasing the risk of infection.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 2006</start_date>
  <completion_date type="Actual">January 2008</completion_date>
  <primary_completion_date type="Actual">December 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hematocrit</measure>
    <time_frame>Day 7, Day 14, Day 21, Day 28</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum Iron Concentration</measure>
    <time_frame>Day 7, Day 14, Day 21, Day 28</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum Ferritin Concentration</measure>
    <time_frame>Day 7, Day 14, Day 21, Day 28</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Erythrocyte Zinc Protoporphyrin Concentration</measure>
    <time_frame>Day 7, Day 14, Day 21, Day 28</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects That Received at Least One RBC Transfusion During Admission to the Hospital</measure>
    <time_frame>Throughout hospital stay up to 6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects That Incurred at Least One Infection Throughout Hospital Admission</measure>
    <time_frame>Throughout hospital stay up to 6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Instance of Drug-related Constipation Throughout Hospital Admission</measure>
    <time_frame>Throughout hospital stay up to 6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average Number of Days That Subjects Were Taking Antibiotics</measure>
    <time_frame>Throughout hospital stay up to 6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital Mortality, as Measured by Number of Subject Deaths While Admitted to Hospital</measure>
    <time_frame>Throughout hospital stay up to 6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average Length of Stay in the Hospital</measure>
    <time_frame>Throughout hospital stay up to 6 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">200</enrollment>
  <condition>Anemic, Critically Ill Patients</condition>
  <arm_group>
    <arm_group_label>Iron Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ferrous sulfate 325 mg either by capsule or oral solution three times a day at 9 am, 1pm and 5 pm until hospital discharge or for 42 days, whichever occurs first.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo capsule three times a day at 9 am, 1pm and 5 pm until hospital discharge or for 42 days, whichever occurs first.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ferrous Sulfate</intervention_name>
    <description>Iron group</description>
    <arm_group_label>Iron Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Oral Tablet</intervention_name>
    <description>Placebo group</description>
    <arm_group_label>Placebo Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt; 18 years

          -  Anemia (Hemoglobin &lt; 13.0 g/dL)

          -  â‰¤ 72 hours from hospital admission

          -  Current tolerance of enteral medications

          -  Expected ICU LOS &gt; 5 days

        Exclusion Criteria:

          -  Active bleeding

          -  Chronic inflammatory disease

          -  End-stage renal disease

          -  Hematologic disorders

          -  Macrocytic anemia

          -  Current use of erythropoietin

          -  Pregnancy

          -  Prohibition of RBC transfusions

          -  Moribund state in which death is imminent

          -  Enrollment in another clinical trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Philip S Barie, MD, MBA</last_name>
    <role>Principal Investigator</role>
    <affiliation>Weill Medical College of Cornell University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Weill Medical College of Cornell University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>March 20, 2007</study_first_submitted>
  <study_first_submitted_qc>March 20, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 21, 2007</study_first_posted>
  <results_first_submitted>April 24, 2019</results_first_submitted>
  <results_first_submitted_qc>April 24, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">July 8, 2019</results_first_posted>
  <last_update_submitted>July 8, 2019</last_update_submitted>
  <last_update_submitted_qc>July 8, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 18, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>iron</keyword>
  <keyword>critical illness</keyword>
  <keyword>anemia</keyword>
  <keyword>infection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Critical Illness</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Iron Group</title>
          <description>Ferrous sulfate 325 mg either by capsule or oral solution three times a day at 9 am, 1pm and 5 pm until hospital discharge or for 42 days, whichever occurs first.
Ferrous Sulfate: Iron group</description>
        </group>
        <group group_id="P2">
          <title>Placebo Group</title>
          <description>Placebo capsule three times a day at 9 am, 1pm and 5 pm until hospital discharge or for 42 days, whichever occurs first.
Placebo Oral Tablet: Placebo group</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="97"/>
                <participants group_id="P2" count="103"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="88"/>
                <participants group_id="P2" count="92"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Primary Team</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Iron Group</title>
          <description>Ferrous sulfate 325 mg either by capsule or oral solution three times a day at 9 am, 1pm and 5 pm until hospital discharge or for 42 days, whichever occurs first.
Ferrous Sulfate: Iron group</description>
        </group>
        <group group_id="B2">
          <title>Placebo Group</title>
          <description>Placebo capsule three times a day at 9 am, 1pm and 5 pm until hospital discharge or for 42 days, whichever occurs first.
Placebo Oral Tablet: Placebo group</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="97"/>
            <count group_id="B2" value="103"/>
            <count group_id="B3" value="200"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="97"/>
                    <count group_id="B2" value="103"/>
                    <count group_id="B3" value="200"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55.7" spread="1.9"/>
                    <measurement group_id="B2" value="58.2" spread="1.7"/>
                    <measurement group_id="B3" value="57.0" spread="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="97"/>
                    <count group_id="B2" value="103"/>
                    <count group_id="B3" value="200"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="48"/>
                    <measurement group_id="B2" value="55"/>
                    <measurement group_id="B3" value="103"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="49"/>
                    <measurement group_id="B2" value="48"/>
                    <measurement group_id="B3" value="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline hematocrit</title>
          <units>% of RBC in total blood volume</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="97"/>
                    <count group_id="B2" value="103"/>
                    <count group_id="B3" value="200"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32.0" spread="0.5"/>
                    <measurement group_id="B2" value="31.9" spread="0.4"/>
                    <measurement group_id="B3" value="31.9" spread="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline MCV</title>
          <description>Mean Corpuscular Volume (MCV)</description>
          <units>femtoliters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="97"/>
                    <count group_id="B2" value="103"/>
                    <count group_id="B3" value="200"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="88.7" spread="0.7"/>
                    <measurement group_id="B2" value="88.6" spread="0.8"/>
                    <measurement group_id="B3" value="88.6" spread="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline EBL</title>
          <description>Estimated Blood Loss (EBL)</description>
          <units>milliliters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="97"/>
                    <count group_id="B2" value="103"/>
                    <count group_id="B3" value="200"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="171" spread="45"/>
                    <measurement group_id="B2" value="207" spread="50"/>
                    <measurement group_id="B3" value="189" spread="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline RBC transfusion</title>
          <description>Red Blood Cell (RBC)</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="97"/>
                    <count group_id="B2" value="103"/>
                    <count group_id="B3" value="200"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline RBC transfusion</title>
          <description>Red Blood Cell (RBC)</description>
          <units>milliliters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="97"/>
                    <count group_id="B2" value="103"/>
                    <count group_id="B3" value="200"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="135" spread="58"/>
                    <measurement group_id="B2" value="303" spread="110"/>
                    <measurement group_id="B3" value="222" spread="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Admission to enrollment</title>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="97"/>
                    <count group_id="B2" value="103"/>
                    <count group_id="B3" value="200"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.6" spread="0.1"/>
                    <measurement group_id="B2" value="1.7" spread="0.1"/>
                    <measurement group_id="B3" value="1.7" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Admission APACHE II</title>
          <description>Acute Physiology and Chronic Health Evaluation (APACHE): Designed to measure the severity of disease for adult patients admitted to intensive care units. The point score is calculated from a patient's age and 12 routine physiological measurements: alveolar-arterial oxygen gradient or arterial blood gasses, temperature, mean arterial pressure, pH arterial, heart rate, respiratory rate, sodium (serum), potassium (serum), creatinine, hematocrit, white blood cell count, glasgow coma scale. The APACHE score ranges from 0 to 71, with 0 indicating a higher mortality risk and 71 a lower risk.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="97"/>
                    <count group_id="B2" value="103"/>
                    <count group_id="B3" value="200"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15.9" spread="0.8"/>
                    <measurement group_id="B2" value="14.9" spread="0.8"/>
                    <measurement group_id="B3" value="15.4" spread="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Hematocrit</title>
        <time_frame>Day 7, Day 14, Day 21, Day 28</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Iron Group</title>
            <description>Ferrous sulfate 325 mg either by capsule or oral solution three times a day at 9 am, 1pm and 5 pm until hospital discharge or for 42 days, whichever occurs first.
Ferrous Sulfate: Iron group</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>Placebo capsule three times a day at 9 am, 1pm and 5 pm until hospital discharge or for 42 days, whichever occurs first.
Placebo Oral Tablet: Placebo group</description>
          </group>
        </group_list>
        <measure>
          <title>Hematocrit</title>
          <units>percentage of RBC in blood</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="97"/>
                <count group_id="O2" value="103"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.3" spread="0.5"/>
                    <measurement group_id="O2" value="29.1" spread="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.6" spread="0.4"/>
                    <measurement group_id="O2" value="28.2" spread="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.2" spread="0.4"/>
                    <measurement group_id="O2" value="28.1" spread="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.8" spread="0.6"/>
                    <measurement group_id="O2" value="28.1" spread="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Serum Iron Concentration</title>
        <time_frame>Day 7, Day 14, Day 21, Day 28</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Iron Group</title>
            <description>Ferrous sulfate 325 mg either by capsule or oral solution three times a day at 9 am, 1pm and 5 pm until hospital discharge or for 42 days, whichever occurs first.
Ferrous Sulfate: Iron group</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>Placebo capsule three times a day at 9 am, 1pm and 5 pm until hospital discharge or for 42 days, whichever occurs first.
Placebo Oral Tablet: Placebo group</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Iron Concentration</title>
          <units>mcg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="97"/>
                <count group_id="O2" value="103"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35" spread="0.6"/>
                    <measurement group_id="O2" value="37" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34" spread="0.5"/>
                    <measurement group_id="O2" value="34" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34" spread="0.6"/>
                    <measurement group_id="O2" value="40" spread="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37" spread="0.5"/>
                    <measurement group_id="O2" value="36" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Serum Ferritin Concentration</title>
        <time_frame>Day 7, Day 14, Day 21, Day 28</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Iron Group</title>
            <description>Ferrous sulfate 325 mg either by capsule or oral solution three times a day at 9 am, 1pm and 5 pm until hospital discharge or for 42 days, whichever occurs first.
Ferrous Sulfate: Iron group</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>Placebo capsule three times a day at 9 am, 1pm and 5 pm until hospital discharge or for 42 days, whichever occurs first.
Placebo Oral Tablet: Placebo group</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Ferritin Concentration</title>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="97"/>
                <count group_id="O2" value="103"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="280" spread="46"/>
                    <measurement group_id="O2" value="265" spread="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="268" spread="51"/>
                    <measurement group_id="O2" value="268" spread="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="251" spread="40"/>
                    <measurement group_id="O2" value="355" spread="83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="383" spread="54"/>
                    <measurement group_id="O2" value="361" spread="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Erythrocyte Zinc Protoporphyrin Concentration</title>
        <time_frame>Day 7, Day 14, Day 21, Day 28</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Iron Group</title>
            <description>Ferrous sulfate 325 mg either by capsule or oral solution three times a day at 9 am, 1pm and 5 pm until hospital discharge or for 42 days, whichever occurs first.
Ferrous Sulfate: Iron group</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>Placebo capsule three times a day at 9 am, 1pm and 5 pm until hospital discharge or for 42 days, whichever occurs first.
Placebo Oral Tablet: Placebo group</description>
          </group>
        </group_list>
        <measure>
          <title>Erythrocyte Zinc Protoporphyrin Concentration</title>
          <units>micromol:mol heme</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="97"/>
                <count group_id="O2" value="103"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69" spread="4"/>
                    <measurement group_id="O2" value="67" spread="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75" spread="6"/>
                    <measurement group_id="O2" value="77" spread="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86" spread="5"/>
                    <measurement group_id="O2" value="91" spread="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84" spread="6"/>
                    <measurement group_id="O2" value="89" spread="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects That Received at Least One RBC Transfusion During Admission to the Hospital</title>
        <time_frame>Throughout hospital stay up to 6 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Iron Group</title>
            <description>Ferrous sulfate 325 mg either by capsule or oral solution three times a day at 9 am, 1pm and 5 pm until hospital discharge or for 42 days, whichever occurs first.
Ferrous Sulfate: Iron group</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>Placebo capsule three times a day at 9 am, 1pm and 5 pm until hospital discharge or for 42 days, whichever occurs first.
Placebo Oral Tablet: Placebo group</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects That Received at Least One RBC Transfusion During Admission to the Hospital</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="97"/>
                <count group_id="O2" value="103"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.03</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects That Incurred at Least One Infection Throughout Hospital Admission</title>
        <time_frame>Throughout hospital stay up to 6 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Iron Group</title>
            <description>Ferrous sulfate 325 mg either by capsule or oral solution three times a day at 9 am, 1pm and 5 pm until hospital discharge or for 42 days, whichever occurs first.
Ferrous Sulfate: Iron group</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>Placebo capsule three times a day at 9 am, 1pm and 5 pm until hospital discharge or for 42 days, whichever occurs first.
Placebo Oral Tablet: Placebo group</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects That Incurred at Least One Infection Throughout Hospital Admission</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="97"/>
                <count group_id="O2" value="103"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45"/>
                    <measurement group_id="O2" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Instance of Drug-related Constipation Throughout Hospital Admission</title>
        <time_frame>Throughout hospital stay up to 6 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Iron Group</title>
            <description>Ferrous sulfate 325 mg either by capsule or oral solution three times a day at 9 am, 1pm and 5 pm until hospital discharge or for 42 days, whichever occurs first.
Ferrous Sulfate: Iron group</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>Placebo capsule three times a day at 9 am, 1pm and 5 pm until hospital discharge or for 42 days, whichever occurs first.
Placebo Oral Tablet: Placebo group</description>
          </group>
        </group_list>
        <measure>
          <title>Instance of Drug-related Constipation Throughout Hospital Admission</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="97"/>
                <count group_id="O2" value="103"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Average Number of Days That Subjects Were Taking Antibiotics</title>
        <time_frame>Throughout hospital stay up to 6 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Iron Group</title>
            <description>Ferrous sulfate 325 mg either by capsule or oral solution three times a day at 9 am, 1pm and 5 pm until hospital discharge or for 42 days, whichever occurs first.
Ferrous Sulfate: Iron group</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>Placebo capsule three times a day at 9 am, 1pm and 5 pm until hospital discharge or for 42 days, whichever occurs first.
Placebo Oral Tablet: Placebo group</description>
          </group>
        </group_list>
        <measure>
          <title>Average Number of Days That Subjects Were Taking Antibiotics</title>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="97"/>
                <count group_id="O2" value="103"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14" spread="2"/>
                    <measurement group_id="O2" value="16" spread="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hospital Mortality, as Measured by Number of Subject Deaths While Admitted to Hospital</title>
        <time_frame>Throughout hospital stay up to 6 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Iron Group</title>
            <description>Ferrous sulfate 325 mg either by capsule or oral solution three times a day at 9 am, 1pm and 5 pm until hospital discharge or for 42 days, whichever occurs first.
Ferrous Sulfate: Iron group</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>Placebo capsule three times a day at 9 am, 1pm and 5 pm until hospital discharge or for 42 days, whichever occurs first.
Placebo Oral Tablet: Placebo group</description>
          </group>
        </group_list>
        <measure>
          <title>Hospital Mortality, as Measured by Number of Subject Deaths While Admitted to Hospital</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="97"/>
                <count group_id="O2" value="103"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Average Length of Stay in the Hospital</title>
        <time_frame>Throughout hospital stay up to 6 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Iron Group</title>
            <description>Ferrous sulfate 325 mg either by capsule or oral solution three times a day at 9 am, 1pm and 5 pm until hospital discharge or for 42 days, whichever occurs first.
Ferrous Sulfate: Iron group</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>Placebo capsule three times a day at 9 am, 1pm and 5 pm until hospital discharge or for 42 days, whichever occurs first.
Placebo Oral Tablet: Placebo group</description>
          </group>
        </group_list>
        <measure>
          <title>Average Length of Stay in the Hospital</title>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="97"/>
                <count group_id="O2" value="103"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14" spread="1"/>
                    <measurement group_id="O2" value="16" spread="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Iron Group</title>
          <description>Ferrous sulfate 325 mg either by capsule or oral solution three times a day at 9 am, 1pm and 5 pm until hospital discharge or for 42 days, whichever occurs first.
Ferrous Sulfate: Iron group</description>
        </group>
        <group group_id="E2">
          <title>Placebo Group</title>
          <description>Placebo capsule three times a day at 9 am, 1pm and 5 pm until hospital discharge or for 42 days, whichever occurs first.
Placebo Oral Tablet: Placebo group</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="97"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal upset</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="97"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Philip S. Barie, MD</name_or_title>
      <organization>Weill Cornell Medical College</organization>
      <phone>646-962-2580</phone>
      <email>pbarie@med.cornell.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

